Dana Albon

590 total citations
31 papers, 332 citations indexed

About

Dana Albon is a scholar working on Pulmonary and Respiratory Medicine, General Health Professions and Epidemiology. According to data from OpenAlex, Dana Albon has authored 31 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 10 papers in General Health Professions and 5 papers in Epidemiology. Recurrent topics in Dana Albon's work include Cystic Fibrosis Research Advances (24 papers), Tracheal and airway disorders (5 papers) and Geriatric Care and Nursing Homes (4 papers). Dana Albon is often cited by papers focused on Cystic Fibrosis Research Advances (24 papers), Tracheal and airway disorders (5 papers) and Geriatric Care and Nursing Homes (4 papers). Dana Albon collaborates with scholars based in United States. Dana Albon's co-authors include Lindsay Somerville, Larry Borish, Rachel Murray, Lijia Zhang, Anna Smith, Thida Ong, Kathryn A. Sabadosa, Michael S. Schechter, Scott K. Heysell and Peter Scalia and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Dana Albon

28 papers receiving 325 citations

Peers

Countries citing papers authored by Dana Albon

Since Specialization

Citations

This map shows the geographic impact of Dana Albon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Albon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Albon more than expected).

Fields of papers citing papers by Dana Albon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Albon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Albon. The network helps show where Dana Albon may publish in the future.

Co-authorship network of co-authors of Dana Albon

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Albon. A scholar is included among the top collaborators of Dana Albon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Albon. Dana Albon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID‐19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model 2025 ·Pediatric Pulmonology ·Dana Albon, Thida Ong, Bethany J. Horton, (unknown), Shiyi Shen, (unknown), Nicholas Antos, Fadi Asfour, (unknown), (unknown), Cori Daines, Deborah Froh, (unknown), Samya Z. Nasr, Meghana Sathe, G. Sawicki, Michael S. Schechter, George M. Solomon, Michael R. Powers	0
2	Reconsidering the Diagnosis: Abnormal Sweat Chloride Tests in Non‐CF Bronchiectasis 2025 ·Pediatric Pulmonology ·(unknown), (unknown), (unknown), Dana Albon	0
3	Cutaneous manifestations of cystic fibrosis 2024 ·Journal of the American Academy of Dermatology ·(unknown), (unknown), (unknown), Richard Flowers, Dana Albon, Kenneth E. Greer, (unknown), (unknown)	1
4	Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population 2024 ·Therapeutic Advances in Respiratory Disease ·Lindsay Somerville, (unknown), (unknown), Dana Albon	4
5	Interventions to improve system-level coproduction in the Cystic Fibrosis Learning Network 2024 ·BMJ Open Quality ·(unknown), Dana Albon, (unknown), (unknown), (unknown), Kathryn A. Sabadosa, Michael Seid, (unknown), Thida Ong	2
6	Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis 2023 ·Pediatric Pulmonology ·(unknown), (unknown), (unknown), (unknown), Aaron D. Smith, Andrew Barros, Lindsay Somerville, Dana Albon	5
7	Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative 2023 ·BMJ Open Quality ·(unknown), George M. Solomon, (unknown), Bethany J. Horton, Shiyi Shen, (unknown), Hossein Sadeghi, Maria T. Britto, Clement L. Ren, Dana Albon	4
8	Real world study on elexacaftor‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis 2023 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Andrew Barros, Lindsay Somerville, Dana Albon	6
9	The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis 2023 ·Allergy Asthma and Clinical Immunology ·Ankur Mehta, (unknown), (unknown), Malcolm K. Jones, (unknown), (unknown), (unknown), Larry Borish, Dana Albon	6
10	Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis 2022 ·Therapeutic Advances in Respiratory Disease ·(unknown), Dana Albon, (unknown), (unknown)	35
11	Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States 2022 ·Journal of Cystic Fibrosis ·(unknown), Dana Albon, (unknown), Patrick A. Flume, (unknown), Elizabeth A. Cromwell	2
12	3D Single-Breath Chemical Shift Imaging Hyperpolarized Xe-129 MRI of Healthy, CF, IPF, and COPD Subjects 2022 ·Tomography ·Steven Guan, Nicholas J. Tustison, Kun Qing, Yun M. Shim, John P. Mugler, Talissa A. Altes, Dana Albon, Deborah Froh, Borna Mehrad, James T. Patrie, (unknown), (unknown), (unknown), Jaime F. Mata	7
13	Establishing a Cystic Fibrosis Learning Network: Interventions to promote collaboration and data‐driven improvement at scale 2022 ·Learning Health Systems ·Thida Ong, Dana Albon, Raouf Amin, Julianna Bailey, (unknown), Maria T. Britto, (unknown), (unknown), Michael R. Powers, Kathryn A. Sabadosa, (unknown), (unknown), (unknown), Michael Seid, (unknown)	14
14	Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors 2021 ·Journal of Cystic Fibrosis ·Dana Albon, Aricca D. Van Citters, Thida Ong, (unknown), Christopher F. Dowd, Anne Willis, Kathryn A. Sabadosa, Peter Scalia, (unknown), Gabriela R. Oates, Michael S. Schechter	35
15	Real-World Outcomes in Cystic Fibrosis Telemedicine Clinical Care in a Time of a Global Pandemic 2021 ·CHEST Journal ·Lindsay Somerville, (unknown), (unknown), (unknown), (unknown), (unknown), Rachel Murray, (unknown), (unknown), (unknown), Dana Albon	11
16	Preserving Multidisciplinary Care Model and Patient Safety During Reopening of Ambulatory Cystic Fibrosis Clinic for Nonurgent Care: A Hybrid Telehealth Model 2020 ·Telemedicine Journal and e-Health ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lindsay Somerville, Dana Albon	17
17	A Feasibility Study of Urgent Implementation of Cystic Fibrosis Multidisciplinary Telemedicine Clinic in the Face of COVID-19 Pandemic: Single-Center Experience 2020 ·Telemedicine Journal and e-Health ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lindsay Somerville, Dana Albon	45
18	Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series 2020 ·Allergy Asthma and Clinical Immunology ·Lijia Zhang, Larry Borish, Anna Smith, Lindsay Somerville, Dana Albon	18
19	Cystic Fibrosis, Iron Deficiency, and Anemia 2018 ·Journal of the Academy of Nutrition and Dietetics ·(unknown), Lori Mankowski Gettle, (unknown), Dana Albon	1
20	A case of massive hemoptysis following transesophageal echocardiogram 2017 ·Respiratory Medicine Case Reports ·Sean J. Callahan, Robert M. Jones, Dana Albon, Andrew D. Mihalek	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact